MBrace Therapeutics Raises $85 Million Series B Financing to Advance Oncology Pipeline of Innovative

– Oversubscribed Series B round led by TPG includes prominent group of new and existing investors, bringing total raised to-date to over $110 million

– Funding supports rapid clinical development of targeted ADC therapeutics in difficult-to-treat cancers

– Chris LeMasters joins as Independent Board Member, bringing 25 years of biotech experience

MBrace Therapeutics Raises $85 Million Series B Financing to Advance Oncology Pipeline of Innovative Antibody Drug Conjugate Candidates | Business Wire